Literature DB >> 15016898

Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Emmanuel Moreau1, Johan Hoebeke, Daniel Zagury, Sylviane Muller, Claude Desgranges.   

Abstract

The human immunodeficiency virus Tat regulatory protein is essential for virus replication and pathogenesis. From human peripheral blood mononuclear cells of three Tat toxoid-immunized volunteers, we isolated five Tat-specific human monoclonal antibodies (HMAbs): two full-length immunoglobulin G (IgG) antibodies and three single-chain fragment-variable (scFv) antibodies. The two IgGs were mapped to distinct epitopes within the basic region of Tat, and the three scFvs were mapped to the N-terminal domain of Tat. The three scFvs were highly reactive with recombinant Tat in Western blotting or immunoprecipitation, but results were in contrast to those for the two IgGs, which are sensitive to a particular folding of the protein. In transactivation assays, scFvs were able to inhibit both active recombinant Tat and native Tat secreted by a transfected CEM cell line while IgGs neutralized only native Tat. These HMAbs were able to reduce viral p24 production in human immunodeficiency virus type 1 strain IIIB chronically infected cell lines in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016898      PMCID: PMC371091          DOI: 10.1128/jvi.78.7.3792-3796.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

Authors:  A Gringeri; E Santagostino; M Muça-Perja; P M Mannucci; J F Zagury; B Bizzini; A Lachgar; M Carcagno; J Rappaport; M Criscuolo; W Blattner; A Burny; R C Gallo; D Zagury
Journal:  J Hum Virol       Date:  1998 May-Jun

3.  Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.

Authors:  J F Zagury; A Sill; W Blattner; A Lachgar; H Le Buanec; M Richardson; J Rappaport; H Hendel; B Bizzini; A Gringeri; M Carcagno; M Criscuolo; A Burny; R C Gallo; D Zagury
Journal:  J Hum Virol       Date:  1998 May-Jun

4.  Tat toxoid as a component of a preventive vaccine in seronegative subjects.

Authors:  A Gringeri; E Santagostino; M Muça-Perja; H Le Buanec; B Bizzini; A Lachgar; J F Zagury; J Rappaport; A Burny; R C Gallo; D Zagury
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-04-01

5.  A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation.

Authors:  H Valvatne; A M Szilvay; D E Helland
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-01       Impact factor: 2.205

6.  A definitive set of oligonucleotide primers for amplifying human V regions.

Authors:  D Sblattero; A Bradbury
Journal:  Immunotechnology       Date:  1998-01

7.  Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation.

Authors:  P M Richalet-Sécordel; N Rauffer-Bruyère; L L Christensen; B Ofenloch-Haehnle; C Seidel; M H Van Regenmortel
Journal:  Anal Biochem       Date:  1997-07-01       Impact factor: 3.365

8.  Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies.

Authors:  I Demirhan; A Chandra; O Hasselmayer; P Chandra
Journal:  FEBS Lett       Date:  1999-02-19       Impact factor: 4.124

9.  Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells.

Authors:  P Secchiero; D Zella; S Capitani; R C Gallo; G Zauli
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

10.  HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells.

Authors:  M Ito; T Ishida; L He; F Tanabe; Y Rongge; Y Miyakawa; H Terunuma
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

View more
  4 in total

1.  A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.

Authors:  Sonia Mediouni; Jennifer D Watkins; Michel Pierres; Angélique Bole; Erwann P Loret; Gilbert Baillat
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

2.  Identification of a highly conserved surface on Tat variants.

Authors:  Sonia Mediouni; Albert Darque; Isabelle Ravaux; Gilbert Baillat; Christian Devaux; Erwann P Loret
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

3.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

4.  Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes.

Authors:  Alessia A Bettaccini; Andreina Baj; Roberto S Accolla; Fulvio Basolo; Antonio Q Toniolo
Journal:  BMC Microbiol       Date:  2005-04-27       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.